I-Mab (NASDAQ:NBP) Downgraded by Wall Street Zen to Hold

Wall Street Zen lowered shares of I-Mab (NASDAQ:NBP) from a buy rating to a hold rating in a research report report published on Saturday morning.

NBP has been the topic of several other reports. Weiss Ratings began coverage on shares of I-Mab in a report on Thursday, February 5th. They issued a “sell (d-)” rating on the stock. HC Wainwright reiterated a “buy” rating and set a $9.00 price target on shares of I-Mab in a research report on Monday, March 16th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, I-Mab has an average rating of “Hold” and a consensus target price of $9.00.

I-Mab Stock Down 4.8%

Shares of NASDAQ:NBP opened at $2.56 on Friday. The company has a market cap of $295.14 million, a PE ratio of -7.11 and a beta of 1.60. I-Mab has a one year low of $0.60 and a one year high of $6.79.

I-Mab (NASDAQ:NBP) last issued its quarterly earnings results on Thursday, December 18th. The company reported ($0.07) EPS for the quarter.

Institutional Trading of I-Mab

A hedge fund recently bought a new stake in I-Mab stock. Brooklyn Investment Group bought a new position in I-Mab (NASDAQ:NBP) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 12,715 shares of the company’s stock, valued at approximately $51,000. Institutional investors own 38.38% of the company’s stock.

About I-Mab

I-Mab is a clinical-stage biotechnology company focused on the discovery, development and commercialization of biologic therapies for oncology and immunology indications. The company concentrates on advancing antibody-based therapeutics and other protein biologics intended to modulate the immune system to treat cancer and autoimmune or inflammatory diseases. Its development activities span preclinical research through late-stage clinical trials, with an emphasis on creating targeted, differentiated molecules designed to address unmet medical needs.

Headquartered in China with global development activities, I-Mab operates research and development facilities and engages with clinical investigators and regulatory authorities across multiple geographies to support global clinical programs.